Wan, Cong and Ma, Huimin and Zeng, Xiaowen and Dong, Guanghui and Chen, Jian and You, Jing and Cheng, Fei and Luo, Yuan and Jones, Kevin C. and Zhang, Gan and Yu, Zhiqiang and Peng, Ping’an (2025) DNA Methylation of FAM50B / PTCHD3 Mediates the Relationships between Low Blood Lead Exposure and Neurobehavioral Development of 0–3 Aged Infants : A Prospective Birth Cohort Study in Southern China. Environment & Health. ISSN 2833-8278
Full text not available from this repository.Abstract
Lead, recognized by the World Health Organization as one of the 10 chemicals of major public health concern, ranks as the fourth leading environmental risk factor contributing to the global burden of disease. Nevertheless, the neurodevelopmental consequences of prenatal low-level lead exposure remain inadequately characterized, with limited understanding of its mechanistic underpinnings and a lack of robust biomarkers for susceptibility. In this birth cohort study, we quantified the concentrations of 27 metals along with DNA methylation levels at 12 gene regions in cord blood. Neurodevelopment was assessed longitudinally in infancy using the Ages and Stages Questionnaires (ASQ). Associations between metal exposures and neurodevelopmental outcomes were evaluated via three complementary statistical approaches: mixed-effect models, quantile g-computation, and Bayesian kernel machine regression. Among all metals examined, only lead (mean concentration of 15.3 μg/L) exhibited consistent and statistically significant negative associations with neurodevelopmental performance. A linear dose–response relationship was observed between lead levels and deficits in problem-solving, fine motor, and gross motor skills. Furthermore, we identified four CpG sites within FAM50B and PTCHD3 that mediate the effects of lead exposure and demonstrated strong predictive capacity for neurodevelopmental outcomes using a random forest model. Our results provide novel evidence that even low-level prenatal lead exposure adversely affects early neurodevelopment and implicate FAM50B/PTCHD3 methylation as both a promising biomarker of lead-related neurodevelopmental risk and a potential target for therapeutic intervention.